Company news

ALX Oncology Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

February 27, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

January 26, 2022

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

January 9, 2022

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

December 11, 2021

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

November 10, 2021

ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

November 8, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

November 1, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

October 20, 2021

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

October 6, 2021

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

September 30, 2021

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

September 15, 2021

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

August 11, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

July 27, 2021

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

July 2, 2021

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

June 13, 2021

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

June 9, 2021

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

May 16, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

May 9, 2021

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

April 20, 2021

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

April 4, 2021

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

March 17, 2021

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors

March 14, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

March 3, 2021

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

January 10, 2021

ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

December 13, 2020

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

December 8, 2020

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

December 6, 2020

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

December 6, 2020

ALX Oncology Announces Proposed Public Offering of Common Stock

December 6, 2020

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

November 11, 2020

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors

November 8, 2020

ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

October 27, 2020

ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board

October 5, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer

September 21, 2020

ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights

August 26, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

July 20, 2020

ALX Oncology Announces Pricing of Initial Public Offering

July 15, 2020

← Newer news releases

Calls

Decks

The 5 newest of 8 decks. Every deck is listed under its year.